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Diabetes mellitus is a condition in which the body cannot properly process 
glucose after it is broken down from sugars and carbohydrates in food. It is of   
3 types: a) Type 1 , b)Type 2 , c)Gestational diabetes. Gestational diabetes 
mellitus(GDM) is defined as carbohydrate intolerance of variable severity with 
an onset or first recognition during pregnancy and develops in around 15-17 % 
of all pregnancies. Women with gestational diabetes are found to have a 
diminished insulin secretion by pancreas/body and pregnancy induced insulin 
resistance primarily present due to counter hormones. Normal pregnancy is 
considered to be a diabetogenic state characterized by increased rate and amount 
of insulin release, associated with decreased sensitivity to insulin at cellular 
levels. Many of the changes are results of the progressive rise in the levels of 
oestrogen, progesterone ,human placental lactogen, cortisol and prolactin as 
pregnancy advances .Many of these hormones are insulin antagonists, causing 
insulin resistance in the mother and cause abnormal glucose tolerance in some 
women rendering them to develop gestational diabetes. During early pregnancy, 
glucose crosses the placenta to the foetus by facilitated diffusion resulting in the 
decrease in fasting blood glucose to 50-65 mg%. As pregnancy progresses 3 
factors are responsible for causing post prandial hyperglycaemia: Insulin 
antagonists such as oestrogen, progesterone and human placental lactogen. 
There is three fold rise in serum cortisol and human placenta contains enzymes 
(eg: insulinase) that increase the degradations by potentiating the secretion of 
insulin. 
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The prevalence of GDM varies from 4% to 14% depending on the population 
and the diagnostic methods performed. In India, rates of GDM are estimated to 
be 10-14.3% which is much higher than the west. In a field study in Tamil 
Nadu, performed under the Diabetes in Pregnancy- Awareness and Prevention 
project, of the 4151,3960 and 3945 pregnant women screened in urban, semi-
urban and rural areas, respectively, the prevalence of GDM was 17.8% in the 
urban, 13.8% in the semi urban and 9.9% in the rural areas. The incidence of 
GDM is expected to increase to 20% i.e. one in every 5 pregnant women is 
likely to have GDM by 2020.In India, because of ethnicity,universal screening 
is recommended by Govt of India. Universal screening of all patients attending 
antenatal clinic by doing OGCT with 75gm glucose is done at the first antenatal 
visit. 
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GOI guidelines: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat testing at 32-34 
weeks 
 
 
 
 
 
 
 
Pregnant women in community 
Testing for GDM at 1st antenatal visit 
(75gm oral glucose - 2hr plasma glucose value) 
Positive                                  
(2hr PG >140 mg/dl) 
 
(2hr 
Negative                                 
(2hr PG <140 mg/dl) 
Manage as GDM  
Repeat testing at 24- 28 
weeks 
Positive                       
(2hr PG >140 mg/dl) 
Negative                                 
(2hr PG < 140mg/dl) 
Manage as GDM Manage as normal 
ANC 
Positive                                  
(2hr PG >140 mg/dl 
Negative                                 
(2hr PG <140 mg/dl) 
 
Manage as GDM  
 
Manage as normal 
ANC 
 
 
 
12 
 
ACOG GUIDELINES FOR POSTPARTUM TESTING 
 
➢ As of June 2009, ACOG recommends extending the time period for 
postpartum  GDM screening test from 6weeks postpartum to 6 to 12weks 
postpartum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FBS or 2hr 75g OGTT at 6-12 weeks 
FBS >126 
75 g OGTT > 200 
    DIABETES MANAGEMENT 
Impaired fasting glucose or 
both  
FBS = 100-125 
75 g OGTT = 140-199 
YEARLY ASSESSMENT OF 
GLYCEMIC STATUS 
 
 
 
 
 
 
FBS < 100 
75g OGTT <140 
ASSESS GLYCEMIC STATUS 
EVERY 3 YEARS 
GESTATIONAL DIABETES 
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ACOG advocates selective screening for patients with high risk factors such as 
history of previous GDM, strong family history of diabetes, member of an 
ethnic group with high prevalence of GDM, maternal age more than 35 years, 
obesity, persistent glycosuria, macrosomia (birth weight>4kg), polycystic 
ovarian syndrome, spontaneous abortions, recurrent pregnancy loss and 
unexplained still births. 
GDM is associated with increased fetomaternal morbidity as well as long term 
complications in mother and babies. Attempts to detect unrecognized diabetes 
in pregnancy should be practiced in antenatal clinics which are justified by the 
increased risk of maternal , perinatal and neonatal morbidity mortality among 
women with abnormal OGCT in pregnancy. 
MATERNAL COMPLICATIONS: 
Increased incidence of asymptomatic bacteriuria,Urinary tract infections 
Pre-eclampsia 
Polyhydramnios 
IUD 
Preterm labour 
Prolonged labour, Obstructed labour 
Operative delivery 
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Uterine atony 
Placental abruption 
Infection 
Postpartum haemorrhage 
 
COMPLICATION IN FETUS: 
Macrosomia- increase risk of shoulder dystocia 
Still birth, IUD 
Hypoglycaemia, Hypocalcaemia 
Congenital abnormalities 
Polycythaemia 
Hyperbilirubinemia 
Respiratory distress syndrome 
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LONG TERM COMPLICATIONS IN CHILD: 
Obesity 
Development of type 2 diabetes mellitus during childhood (20%) 
Impaired motor functions 
Higher rates of inattention and hyperactivity 
 
 
 
LONG TERM COMPLICATIONS IN MOTHER: 
GDM recurrence rate- 50% 
Cardiovascular disease – 23% 
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AIM OF STUDY: 
                     To assess the fetomaternal outcome of pregnancy with gestational 
diabetes mellitus(GDM) 
 
 
PRIMARY OBJECTIVE:  
Antenatal patients with abnormal OGCT were identified and followed up till 
6weeks postpartum.  
The prevalence of GDM during my study period is analysed. 
 
 
SECONDARY OBJECTIVE:  
Evaluate the maternal and perinatal morbidity in gestational diabetes mellitus 
complicating antenatal women. 
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INDIAN JOURNAL OF APPLIED RESEARCH: JULY 2016 
Study of Maternal and Perinatal outcome in Pregnancies Complicated by 
Gestational Diabetes Mellitus 
Observations: Prevalence of GDM was 10.55%. Maximum cases were 25-29 
years old (58.6%) & were either Nulliparous (43.7%) or Primiparous (40.2%). 
Mean gestational age for GDM group was 37.44+1.41 weeks & 38.42+1.46 
weeks for controls. Hyperbilirubinemia was the commonest neonatal adverse 
outcome in both GDM & control groups. All 87 GDM women returned to 
normal glycaemic levels in post-partum period. 
 
MATERNAL AND PERINATAL OUTCOMES OF PREGNANCIES 
COMPLICATED WITH PREGESTATIONAL AND GESTATIONAL 
DIABETES MELLITUS IN SAUDI ARABIA 2014 
GDM women are more likely to be delivered by emergency Caesarean Section 
(CS), Odds Ratio (OR) 1.94, 95% Confidence Intervals (CI) (1.14-3.28), 
p=0.008 or elective CS, OR 3.68, 95%CI (2.05-6.58), p<0.001. The adjusted 
OR for delivery by CS (elective and emergency) was 2.6, 95% CI (1.66-4.09). 
The frequency of APGAR scores less than 7in 5 minutes was more among 
neonates of mothers with PGDM compared to those of GDM, however the 
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difference did not reach statistical significance after adjustment for confounding 
factors, adjusted OR 2.36, 95%CI (0.64-8.68), p=0.11. 
The neonates of the mothers with PGDM were significantly heavier when 
compared to those of GDM group, p<0.001; the frequency of macrosomia was 
more than threefold among PGDM group compared to GDM group, adjusted 
OR 3.67, 95% CI (1.75-7.71), p=0.02. Mothers with PGDM have increased 
estimated risk of preterm delivery less than 37 gestation weeks, adjusted OR 
2.63, 95% CI (1.49-4.70), p 0.003. Although there was twofold increase in 
frequency of stillbirth among women with PGDM compared to the GDM group 
the difference was not statistically significant, adjusted OR 1.96, 95%CI (0.45-
8.50), p=0.050. 
 
INDIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM 2016 
PREVALENCE OF GESTATIONAL DIABETES MELLITUS AND ITS 
OUTCOME IN WESTERN RAJASTHAN 
Obesity as a significant risk factor for GDM is supported by several studies 
finding that overweight or obesity at the start of pregnancy predisposes to 
GDM. 
Study revealed that the most common complications seen in GDM mothers 
were gestational hypertension (36.4%) followed by vaginal candidiasis (24.2%), 
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premature rupture of membranes (PROM; 18.1%), and abruptio placentae 
(12.12%) 
 
IOSR JOURNAL OF DENTAL AND MEDICAL SCIENCES (IOSR-
JDMS) APRIL 2015 
The study concluded that risks factors for GDM include increased maternal age, 
obesity, poor past obstetric history, family history of DM and previous history 
of GDM. There was increased frequency of pre-eclampsia, gestational 
hypertension, preterm delivery, operative interference, macrosomia, in GDM in 
women. The increased foetal complications observed in the study were 
intrauterine death, NICU admission, respiratory distress syndrome but the 
overall perinatal outcome was similar to that of normal pregnancies. hence 
considering the risk to the mother and the baby, both during pregnancy and 
perinatal period, screening of GDM and identifying those at risk is important for 
subsequent management and reduction of maternal and perinatal morbidity and 
mortality.   
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JOURNAL OF MEDICINE AND MEDICAL SCIENCE VOL. 2(8) PP. 
1022-1027, AUGUST  2011 
GESTATIONAL DIABETES AND PERINATAL OUTCOMES: A CASE 
CONTROL STUDY.    
The prevalence of the GDM in current study was 13%. The GDM was 
associated with lower 1-min Apgar score, as well as higher rates of macrosomia, 
breech delivery, cesarean section rates and neonatal intensive care admissions. 
On the other hand, an association between the disease and the level of 
schooling, previous stillbirth, low Apgar indexes at the 5th minute, pH in the 
blood of the umbilical artery less than 7.1, and fetal mortality in the current 
pregnancy were not observed.   
 
SCHOLARS JOURNAL OF APPLIED MEDICAL SCIENCES (SJAMS) 
2014 
A CLINICAL STUDY OF MATERNAL COMPLICATIONS AND 
PERINATAL OUTCOMES IN DIABETES COMPLICATING PREGNANCY 
 
Gestational diabetes was more prevalent in the study cohort. Pre-eclampsia 
preterm delivery and polyhydramnios were the most common antenatal 
complications. Preterm delivery was significantly associated with perinatal 
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mortality. Hyperbilirubinemiawas the most common neonatal complication 
requiring NICU admission. Fetal malformations are more common with poor 
metabolic control in early pregnancy. The most frequent malformations 
observed are heart defects.  Infants born to women with GDM were 
significantly larger (mean birth weight 3584±616 gms) 
 
INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC 
HEALTH 2014 VOL 3 
Prevalence of GDM was 14.42%. Stillbirth, Perinatal & neonatal mortality were 
respectively 2, 3.3 & 6 times higher in GDM. Most of the GDM were diagnosed 
in primigravida (62%). Congenital Malformation was 8 times higher. Low Birth 
Weight (LBW) was 35% in GDM (16% in Non GDM). GDM positive cases had 
20.6% positive family history of diabetes (compared to 6.5% in non-GDM). 
Relative risks for PBU (post birth unit), LGA (large for gestational age), LBW 
(low birth weight), pre-eclampsia and jaundice were also higher. 
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MATERIALS AND 
METHODS 
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STUDY CENTRE 
                             DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY 
                             ISO KASTURBA GANDHI HOSPITAL, TRIPLICANE 
                             MADRAS MEDICAL COLLEGE, CHENNAI-5 
 
DURATION OF STUDY 
                              TWO YEARS, JULY 2015 TO JULY 2017 
 
SAMPLE SIZE: 
                            700 patients  
 
STUDY DESIGN 
CROSS SECTIONAL STUDY 
 
METHODOLOGY: 
All antenatal women were subjected to DIPSI Method:  
75g oral glucose challenge test (OGCT) at their first booking visit 
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• Single step procedure. Serves as both screening and diagnostic procedure 
 
• Pregnant women need not be fasting  
 
• Blood sugar 2hours post glucose(75gms) > 140mg/dl by GOD-POD method 
were diagnosed as GDM. 
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SUBJECT SELECTION:  
CASES: 
INCLUSION CRITERIA: 
Antenatal patients of five groups: 
a. GDM on Meal plan  
b. GDM on Oral Hypoglycaemic Drugs 
c. GDM on Insulin 
d. GDM on Oral Hypoglycaemic Drugs and Insulin  
e. Normal antenatal women without GDM 
were identified and followed up for fetomaternal outcome from first antenatal 
visit to 6weeks postpartum. 
 
EXCLUSION CRITERIA:    
 
a. Unwilling to participate in the study 
b. Pregnant women with pre existing diabetes 
c. Twin pregnancy/ abnormal lie or other known complication 
d. Pregnant women who gave birth at home or in another institution    
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CONTROLS: 
                  Pregnant women whose gestational evaluation has not presented any 
clinical or laboratory alteration compatible with GDM.  
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INVESTIGATION DETAILS: 
                   Antenatal patients were followed up from the first booking 
visit till 6weeks postpartum and are studied for fetomaternal outcome of 
pregnancy. 
 
VARIABLES ANALYZED: 
 
The following data will be collected from antenatal patients attending 
antenatal clinic:  
 
MATERNAL AND OBSTETRIC: 
➢ Name 
➢ Age  
➢ BMI  
➢ Family history of diabetes  
➢ Parity 
➢ Period of gestation 
➢ Random blood sugar  
➢ Oral glucose tolerance test  
➢ Previous stillbirth or spontaneous abortion or IUD or 
malformation, macrosomia 
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➢ Weight gain  
➢ Prenatal care  
➢ Identification of complications:  
a) Hypertensive syndrome 
b) Polyhydramnios 
c)Operative interference 
d)Preterm labour 
 
POSTPARTUM:  
• 6 weeks postpartum GTT 
 
FETAL: 
➢ IUD  
➢ Prematurity 
➢ 1 and 5 min Apgar score  
➢ Birth asphyxia  
➢ Birth weight (LBW,IUGR, macrosomia) 
➢ Hypoglycaemia, hyperbilirubinemia 
➢ Congenital defects  
➢ Neonatal intensive care admissions(along with cause) 
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OBSERVATIONS AND 
RESULTS 
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AGE GROUP 
 
 
GROUP 
Total GDM NO GDM 
AGE GROUP UPTO 19 Count 1 34 35 
% within GROUP 1.0% 5.7% 5.0% 
% of Total 0.1% 4.9% 5.0% 
20-25 Count 33 347 380 
% within GROUP 31.7% 58.2% 54.3% 
% of Total 4.7% 49.6% 54.3% 
26-30 Count 46 169 215 
% within GROUP 44.2% 28.4% 30.7% 
% of Total 6.6% 24.1% 30.7% 
31-35 Count 21 36 57 
% within GROUP 20.2% 6.0% 8.1% 
% of Total 3.0% 5.1% 8.1% 
>35 Count 3 10 13 
% within GROUP 2.9% 1.7% 1.9% 
% of Total 0.4% 1.4% 1.9% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
 
 
Pearson Chi-Square 45.170 
p value 0.00 
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GRAVIDA GROUP 
GROUP 
Total GDM NO GDM 
GRAVIDA 1 Count 42 315 357 
% within GROUP 40.4% 52.9% 51.0% 
% of Total 6.0% 45.0% 51.0% 
2 Count 42 191 233 
% within GROUP 40.4% 32.0% 33.3% 
% of Total 6.0% 27.3% 33.3% 
3 Count 12 64 76 
% within GROUP 11.5% 10.7% 10.9% 
% of Total 1.7% 9.1% 10.9% 
4 Count 4 18 22 
% within GROUP 3.8% 3.0% 3.1% 
% of Total 0.6% 2.6% 3.1% 
5 Count 2 6 8 
% within GROUP 1.9% 1.0% 1.1% 
% of Total 0.3% 0.9% 1.1% 
6 Count 2 0 2 
% within GROUP 1.9% 0.0% 0.3% 
% of Total 0.3% 0.0% 0.3% 
7 Count 0 2 2 
% within GROUP 0.0% 0.3% 0.3% 
% of Total 0.0% 0.3% 0.3% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
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GRAVIDA GROUP 
 
 
Pearson Chi-Square 17.254   
p value      0.008 
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LIVE GROUP 
 
 
GROUP 
Total GDM NO GDM 
LIVE 0 Count 60 377 437 
% within GROUP 57.7% 63.3% 62.4% 
% of Total 8.6% 53.9% 62.4% 
1 Count 43 193 236 
% within GROUP 41.3% 32.4% 33.7% 
% of Total 6.1% 27.6% 33.7% 
2 Count 1 26 27 
% within GROUP 1.0% 4.4% 3.9% 
% of Total 0.1% 3.7% 3.9% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
Pearson Chi-Square 5.204  
p value                 0.074 
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ABORTION  GROUP 
 
 
GROUP 
Total GDM NO GDM 
ABORTION 0 Count 78 502 580 
% within GROUP 75.0% 84.2% 82.9% 
% of Total 11.1% 71.7% 82.9% 
1 Count 17 70 87 
% within GROUP 16.3% 11.7% 12.4% 
% of Total 2.4% 10.0% 12.4% 
2 Count 6 18 24 
% within GROUP 5.8% 3.0% 3.4% 
% of Total 0.9% 2.6% 3.4% 
3 Count 2 6 8 
% within GROUP 1.9% 1.0% 1.1% 
% of Total 0.3% 0.9% 1.1% 
4 Count 1 0 1 
% within GROUP 1.0% 0.0% 0.1% 
% of Total 0.1% 0.0% 0.1% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
Pearson Chi-Square 10.752  
p value                       0.030 
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F/H/GDM GROUP 
 
 
 
 
GROUP 
Total GDM NO GDM 
F/H/GDM NO Count 84 496 580 
% within GROUP 80.8% 83.2% 82.9% 
% of Total 12.0% 70.9% 82.9% 
YES Count 20 100 120 
% within GROUP 19.2% 16.8% 17.1% 
% of Total 2.9% 14.3% 17.1% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
Pearson Chi-Square 0.375   
P value               0.540 
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PREV LSCS GROUP 
 
 
GROUP 
Total GDM NO GDM 
PREV LSCS NO Count 74 540 614 
% within GROUP 71.2% 90.6% 87.7% 
% of Total 10.6% 77.1% 87.7% 
YES Count 30 56 86 
% within GROUP 28.8% 9.4% 12.3% 
% of Total 4.3% 8.0% 12.3% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
 
Pearson Chi-Square 31.086 
 p value                0.000 
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PREV H/O GDM GROUP 
 
 
GROUP 
Total GDM NO GDM 
PREV H/O GDM NO Count 92 596 688 
% within GROUP 88.5% 100.0% 98.3% 
% of Total 13.1% 85.1% 98.3% 
YES Count 12 0 12 
% within GROUP 11.5% 0.0% 1.7% 
% of Total 1.7% 0.0% 1.7% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
 
Pearson Chi-Square 69.969 
p value                      0.000 
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BMI GROUP  
 
 
GROUP 
Total GDM NO GDM 
BMI GROUP NORMAL Count 14 228 242 
% within GROUP 13.5% 38.3% 34.6% 
% of Total 2.0% 32.6% 34.6% 
OVER  WEIGHT Count 56 233 289 
% within GROUP 53.8% 39.1% 41.3% 
% of Total 8.0% 33.3% 41.3% 
OBESE Count 34 135 169 
% within GROUP 32.7% 22.7% 24.1% 
% of Total 4.9% 19.3% 24.1% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
% of Total 14.9% 85.1% 100.0% 
 
 
 
Pearson Chi-Square 24.111     
p value 0.000 
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PIH  GROUP 
 
 
GROUP 
Total GDM NO GDM 
PIH NO Count 81 558 639 
% within GROUP 77.9% 93.6% 91.3% 
YES Count 18 34 52 
% within GROUP 17.3% 5.7% 7.4% 
2 Count 5 4 9 
% within GROUP 4.8% 0.7% 1.3% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
    
 
 
 
Pearson Chi-Square 30.235 
p value                    0.000 
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OPERATIVE DELIVERY  GROUP 
 
 
 
GROUP 
Total GDM NO GDM 
OPERATIVE DELIVERY NO Count 19 342 361 
% within GROUP 18.3% 57.4% 51.6% 
YES Count 85 254 339 
% within GROUP 81.7% 42.6% 48.4% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
 
Pearson Chi-Square 54.240 
p value                             0.000 
 
Operative delivery was found to be common in women with 
OGCT  >124 
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ROC curve 
Variable SUGAR 
Classification variable OPERATIVE_DELIVERY 
OPERATIVE DELIVERY 
Sample size   396 
Positive group :  OPERATIVE DELIVERY = 1 212 
Negative group :  OPERATIVE DELIVERY = 0 184 
Disease prevalence (%) unknown 
Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.670 
Standard Errora 0.0272 
95% Confidence intervalb 0.621 to 0.716 
z statistic 6.256 
Significance level P (Area=0.5) <0.0001 
a DeLong et al., 1988 
b Binomial exact 
Youden index 
Youden index J 0.3180 
Associated criterion >124 
Sensitivity 41.04 
Specificity 90.76 
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 Specificity: 90.8
 Criterion : >124
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TERM/PRETERM  GROUP 
 
 
GROUP 
Total GDM NO GDM 
TERM/PRETERM TERM Count 72 483 555 
% within GROUP 69.2% 81.0% 79.3% 
PRE TERM Count 32 113 145 
% within GROUP 30.8% 19.0% 20.7% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
 
Pearson Chi-Square 7.519  
p value                            0.006 
 
 
 
 
Preterm babies were common in women with                          
OGCT  > 172. 
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ROC curve 
Variable SUGAR 
Classification variable TERM_PRETERM 
TERM/PRETERM 
Sample size   102 
Positive group :  TERM/PRETERM = 1 30 
Negative group :  TERM/PRETERM = 0 72 
Disease prevalence (%) unknown 
Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.531 
Standard Errora 0.0642 
95% Confidence intervalb 0.430 to 0.631 
z statistic 0.483 
Significance level P (Area=0.5) 0.6291 
a DeLong et al., 1988 
b Binomial exact 
Youden index 
Youden index J 0.1139 
Associated criterion >172 
Sensitivity 43.33 
Specificity 68.06 
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 Specificity: 68.1
 Criterion : >172
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BABY WEIGHT GROUP  
 
 
GROUP 
Total GDM NO GDM 
BABY WT GROUP NORMAL Count 81 429 510 
% within GROUP 77.9% 72.0% 72.9% 
IUD Count 1 24 25 
% within GROUP 1.0% 4.0% 3.6% 
LBW Count 19 139 158 
% within GROUP 18.3% 23.3% 22.6% 
MACROSOME Count 3 4 7 
% within GROUP 2.9% 0.7% 1.0% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
Pearson Chi-Square 8.093 
p value                        0.044 
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NICU GROUP 
 
 
GROUP 
Total GDM NO GDM 
NICU NO Count 
61 504 565 
% within GROUP 58.7% 84.6% 80.7% 
YES Count 43 92 135 
% within GROUP 41.3% 15.4% 19.3% 
Total Count 
104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
 
 
Pearson Chi-Square 38.188 
p value                           0.000 
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RDS GROUP 
 
 
 
 
GROUP 
Total GDM NO GDM 
RDS NO Count 80 546 626 
% within GROUP 76.9% 91.6% 89.4% 
YES Count 24 50 74 
% within GROUP 23.1% 8.4% 10.6% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
Pearson Chi-Square 20.206  
p value                          0.000 
 
 
RDS was found to common in women with OGCT  > 120 
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ROC curve 
Variable SUGAR 
Classification variable RDS 
Sample size   400 
Positive group :  RDS = 1 49 
Negative group :  RDS = 0 351 
Disease prevalence (%) unknown 
Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.600 
Standard Errora 0.0443 
95% Confidence intervalb 0.550 to 0.649 
z statistic 2.265 
Significance level P (Area=0.5) 0.0235 
a DeLong et al., 1988 
b Binomial exact 
Youden index 
Youden index J 0.1959 
Associated criterion >120 
Sensitivity 46.94 
Specificity 72.65 
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LBW (IUGR)GROUP 
 
 
GROUP 
Total GDM NO GDM 
LBW NO Count 93 538 631 
% within GROUP 89.4% 90.3% 90.1% 
YES Count 11 58 69 
% within GROUP 10.6% 9.7% 9.9% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
Pearson Chi-Square 0.071  
p value                        0.790 
 
 
 
 
LBW (IUGR) was common in women with OGCT < 106 
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ROC curve 
Variable SUGAR 
Classification variable LBW 
Sample size   400 
Positive group :  LBW = 1 40 
Negative group :  LBW = 0 360 
Disease prevalence (%) unknown 
Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.532 
Standard Errora 0.0509 
95% Confidence intervalb 0.482 to 0.582 
z statistic 0.625 
Significance level P (Area=0.5) 0.5317 
a DeLong et al., 1988 
b Binomial exact 
Youden index 
Youden index J 0.1167 
Associated criterion ≤106 
Sensitivity 67.50 
Specificity 44.17 
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PIH vs LBW 
 
 
 
 
 
LBW 
Total NO YES 
PIH NO Count 
71 10 81 
% within LBW 
76.3% 90.9% 77.9% 
YES Count 
17 1 18 
% within LBW 
18.3% 9.1% 17.3% 
2 Count 
5 0 5 
% within LBW 
5.4% 0.0% 4.8% 
Total Count 
93 11 104 
% within LBW 
100.0% 100.0% 100.0% 
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MACROSOMIA GROUP 
 
 
GROUP 
Total GDM NO GDM 
MACRO NO Count 96 594 690 
% within GROUP 92.3% 99.7% 98.6% 
YES Count 8 2 10 
% within GROUP 7.7% 0.3% 1.4% 
Total Count 104 596 700 
% within GROUP 100.0% 100.0% 100.0% 
 
 
 
Pearson Chi-Square 34.033 
p value                        0.000 
 
 
 
 
 
Macrosomia was found to be common in women with 
OGCT value  >133 
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ROC curve 
Variable SUGAR 
Classification variable MACRO 
Sample size   400 
Positive group :  MACRO = 1 9 
Negative group :  MACRO = 0 391 
Disease prevalence (%) unknown 
Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.820 
Standard Errora 0.0907 
95% Confidence intervalb 0.778 to 0.856 
z statistic 3.524 
Significance level P (Area=0.5) 0.0004 
a DeLong et al., 1988 
b Binomial exact 
Youden index 
Youden index J 0.6792 
Associated criterion >133 
Sensitivity 88.89 
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BMI GROUP  vs MEAL PLAN/OHA/INSULIN 
 
 
MEAL PLAN/OHA/INSULIN 
MEAL PLAN OHA INSULIN 
BMI GROUP NORMAL Count 10 1 3 
% within MEAL 
PLAN/OHA/INSULIN 
13.9% 6.3% 18.8% 
OVER  WEIGHT Count 41 9 6 
% within MEAL 
PLAN/OHA/INSULIN 
56.9% 56.3% 37.5% 
OBESE Count 21 6 7 
% within MEAL 
PLAN/OHA/INSULIN 
29.2% 37.5% 43.8% 
Total Count 72 16 16 
% within MEAL 
PLAN/OHA/INSULIN 
100.0% 100.0% 100.0% 
 
 
 Total 
BMI GROUP NORMAL Count 14 
% within MEAL PLAN/OHA/INSULIN 13.5% 
OVER  WEIGHT Count 56 
% within MEAL PLAN/OHA/INSULIN 53.8% 
OBESE Count 34 
% within MEAL PLAN/OHA/INSULIN 32.7% 
Total Count 104 
% within MEAL PLAN/OHA/INSULIN 100.0% 
 
 
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
 
 
 
 
 
F/H/GDM vs MEAL PLAN/OHA/INSULIN 
 
 
MEAL PLAN/OHA/INSULIN 
Total MEAL PLAN OHA INSULIN 
F/H/GDM NO Count 61 11 12 84 
% within MEAL 
PLAN/OHA/INSULIN 
84.7% 68.8% 75.0% 80.8% 
YES Count 11 5 4 20 
% within MEAL 
PLAN/OHA/INSULIN 
15.3% 31.3% 25.0% 19.2% 
Total Count 72 16 16 104 
% within MEAL 
PLAN/OHA/INSULIN 
100.0% 100.0% 100.0% 100.0% 
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PREV H/O GDM  vs MEAL PLAN/OHA/INSULIN 
 
 
MEAL PLAN/OHA/INSULIN 
MEAL PLAN OHA INSULIN 
PREV H/O GDM NO Count 70 9 13 
% within MEAL 
PLAN/OHA/INSULIN 
97.2% 56.3% 81.3% 
YES Count 2 7 3 
% within MEAL 
PLAN/OHA/INSULIN 
2.8% 43.8% 18.8% 
Total Count 72 16 16 
% within MEAL 
PLAN/OHA/INSULIN 
100.0% 100.0% 100.0% 
 
    
 
 
 
 Total 
PREV H/O GDM NO Count 92 
% within MEAL PLAN/OHA/INSULIN 88.5% 
YES Count 12 
% within MEAL PLAN/OHA/INSULIN 11.5% 
Total Count 104 
% within MEAL PLAN/OHA/INSULIN 100.0% 
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POSTNATAL FOLLOW UP 
 
 
 
 
 
 
75
13
16
0
10
20
30
40
50
60
70
80
MEAL PLAN OHA INSULIN
COUNT
COUNT
 
 
77 
 
 
 
GROUP N Mean Std. Deviation Std. Error Mean 
AGE GDM 
104 27.43 4.196 0.411 
NO GDM 
596 24.73 3.885 0.159 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
AGE Equal variances assumed 
0.000 2.705 0.418 1.884 
Equal variances not assumed 
0.000 2.705 0.441 1.832 
 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
AGE Equal variances assumed 3.525 
Equal variances not assumed 3.577 
 
 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
AGE Equal variances assumed .000 2.705 .418 1.884 
Equal variances not 
assumed 
.000 2.705 .441 1.832 
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GROUP N Mean Std. Deviation Std. Error Mean 
GRAVIDA GDM 
104 1.92 1.077 0.106 
NO GDM 
596 1.69 0.913 0.037 
 
 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
GRAVIDA Equal variances assumed 0.103 0.748 2.373 698 
Equal variances not assumed   2.115 130.139 
 
 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
GRAVIDA Equal variances assumed 0.018 0.237 0.100 
Equal variances not assumed 0.036 00.237 0.112 
 
 
 
 
 
 
 
t-test for Equality of Means 
95% Confidence Interval of the Difference 
Lower Upper 
GRAVIDA Equal variances assumed 0.041 0.433 
Equal variances not assumed 0.015 0.458 
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GROUP N Mean Std. Deviation Std. Error Mean 
GA GDM 
104 37.28 3.133 0.307 
NO GDM 
596 37.62 3.794 0.155 
 
 
Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df 
GA Equal variances assumed 1.955 0.163 -0.856 698 
Equal variances not assumed 
  -0.979 160.647 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
GA Equal variances assumed 0.392 -0.337 0.394 -1.110 
Equal variances not assumed 
0.329 -0.337 0.344 -1.017 
 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
GA Equal variances assumed 
0.436 
Equal variances not assumed 
0.343 
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GROUP N Mean Std. Deviation Std. Error Mean 
WT GAIN GDM 
104 10.60 1.159 0.114 
NO GDM 
596 10.89 0.815 0.033 
 
 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
WT GAIN Equal variances assumed 19.156 0.000 -3.141 698 
Equal variances not assumed 
  -2.464 121.384 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
WT GAIN Equal variances assumed 
.002 -0.292 0.093 
Equal variances not assumed 
.015 -0.292 0.118 
 
 
 
t-test for Equality of Means 
95% Confidence Interval of the Difference 
Lower Upper 
WT GAIN Equal variances assumed 
-0.474 -0.109 
Equal variances not assumed 
-0.526 -0.057 
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GROUP N Mean Std. Deviation Std. Error Mean 
BMI GDM 
104 28.418 3.8424 0.3768 
NO GDM 
596 26.664 4.3533 0.1783 
 
 
 
Levene's Test for Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df 
BMI Equal variances assumed 7.541 0.006 3.854 698 
Equal variances not assumed 
  4.207 152.980 
 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower 
BMI Equal variances assumed 0.000 1.7539 0.4550 0.8605 
Equal variances not 
assumed 
0.000 1.7539 0.4168 0.9303 
 
 
t-test for Equality of Means 
95% Confidence Interval of the 
Difference 
Upper 
BMI Equal variances assumed 2.6472 
Equal variances not assumed 
2.5774 
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GROUP N Mean Std. Deviation Std. Error Mean 
APGAR GDM 
104 8.26 1.795 0.176 
NO GDM 
596 8.11 2.058 0.084 
 
 
Levene's Test for Equality of Variances 
t-test for Equality of 
Means 
F Sig. t df 
APGAR Equal variances assumed 
0.693 0.405 0.677 698 
Equal variances not assumed 
  0.746 154.250 
 
 
 
t-test for Equality of Means 
Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
APGAR Equal variances assumed 
0.498 0.146 0.215 
Equal variances not assumed 
0.457 0.146 0.195 
 
 
 
 
t-test for Equality of Means 
95% Confidence Interval of the Difference 
Lower Upper 
APGAR Equal variances assumed -0.276 0.567 
Equal variances not assumed 
-0.240 .531 
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➢ In this study, the prevalence of GDM was 14.85% 
 
➢ Prevalence of GDM was more in the age group 26-30yrs (6.6%) 
 
➢ In our study GDM was prevalent among multigravida.                                                                           
In primi the prevalence was 6%, in second gravida 6% and in 3rd gravida 
1.7%. 
 
➢ No significant difference in the rate of abortions was noted. Prevalence of 
abortions was 75% among GDM women and 84.2% among non-GDM. 
 
➢ Family history of diabetes mellitus was noted in 19.2% of our GDM 
women.  
 
➢ Recurrence rate of GDM in women with previous history of GDM was 
found to be 11.5%. 
 
➢ BMI was directly linked with the incidence of GDM. In our study 13.5% 
were normal weight, 53.8 % were overweight, 30% were obese, 2.7% 
were morbidly obese. 
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➢ Operative delivery was found to be increased among the GDM women in 
our study (81.7%) 
 
➢ GDM women were found to have increased risk of association with PIH 
(17.3%) when compared to the non GDM group (5.7%) 
 
➢ Macrosomia in babies was found in about 7.7% of GDM women in our 
group.  
 
➢ In our postnatal follow-up it was found that 27.8% of the women turned 
into type 2 diabetes mellitus. 
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DISCUSSION 
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➢ GDM prevalence worldwide was from 4% to 14%.                                                   
In this study, the prevalence of GDM was 14.85%.                                                         
Compared to European women, the prevalence of GDM has increased 11 
fold in women from the Indian subcontinent.  
 
➢ There was a prevalence of GDM of 6.6% in antenatal women of age 
group 26-30years. In primi ,the prevalence was 6%, in second gravida 
6% and in 3rd gravida 1.7%. 
 
➢ In this study, there was an equal prevalence of abortion in both GDM 
(75%) and non GDM (84.2%) patients. 
 
➢ In 19.2% of the GDM patients, there was a positive family history. 
 
 
➢ The recurrence rate of GDM in antenatal women with previous history 
of GDM was found to be around 11.5% 
 
➢ Moreover, BMI was directly linked with the incidence of GDM. 
According to literature, it is estimated that the risk of developing GDM is 
approximately 2, 4 and 8 times greater in pregnant women who are 
overweight, obese and morbidly obese respectively when compared to the 
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population of appropriate weight. In our study 13.5% were normal 
weight, 53.8 % were overweight, 30% were obese, 2.7% were morbidly 
obese. 
 
 
➢ The most common maternal complication seen in GDM mothers was 
gestational hypertension (17.3%).It may be due to elevated BMI and 
higher maternal age range. Others include polyhydramnios, prolonged 
labour, obstructed labour, caesarean section, uterine atony, postpartum 
haemorrhage, vaginal candidiasis and progression of retinopathy.   
 
 
➢ Increased caesarean rates were noted in the GDM group. 28.8% 
compared to normal group 9.4% The most prevalent indications were 
previous caesarean section, intrapartum foetal distress, failed induction, 
and macrosomia. 
 
➢ All infants born to GDM mothers are at increased risk of congenital 
malformations, neonatal hypoglycaemia and infant respiratory distress 
syndrome. 
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➢ Risk of preterm birth in GDM patients can be due to early induction and 
delivery due to fear of sudden intra uterine death and shoulder dystocia. 
Prevalence of preterm birth was 30.8% among GDM women and 19% 
among non GDM women. 
 
 
➢ Macrosomia was found in 7.7% of GDM women. It is related to the rate 
of foetal hyperinsulinemia induced by maternal hyperglycaemia and 
nutrients that cross the placental barrier.Macrosomia was found to be 
common in women with OGCT value >133 
 
 
➢ Maternal reno vascular disease is most common cause of impaired foetal 
growth in pregnancy complicated by maternal diabetes. Low birth weight/ 
IUGR was found in 18.3% of the GDM patients. Of these GDM patients, 
9.1% were complicated with gestational hypertension/ pre-
eclampsia.LBW (IUGR) was common in women with OGCT < 106.  
 
 
➢ GDM pregnancies are associated with delay in lung maturity of the 
foetus. Pulmonary disorders like respiratory distress syndrome, transient 
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tachypnoea of new-born (TTN), pneumonia, persistent pulmonary 
hypertension are common in GDM mothers. It is due to modified 
carbohydrate metabolism, insulin vs cortisol action, slower adsorption of 
alveolar fluid following caesarean section. Respiratory distress 
syndrome (RDS) was found in 23.1% of neonates of GDM mothers.  
The cut off value of OGCT was found to be >120. 
 
 
 
➢ In the study, by doing OGCT antenatally, out of the 700 patients 
screened, 104 patients were diagnosed as GDM. These patients were 
treated and followed up till delivery. These patients were followed up to 
6-12 weeks postnatally by doing OGTT. 
 
➢ POSTNATAL (6weeks) FOLLOW UP:  
             Out of the 104 GDM patients followed up postnatally, 75 patients 
were under meal plan and were asked to follow up 3 yearly once with 
glycaemic status.14 patients were under oral anti hypoglycaemic drugs 
and 15 patients were under insulin. These 29 patients were asked to 
follow up yearly with glycaemic status. 
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LIMITATIONS 
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➢ Our ﬁndings of this study are largely at tandem with those of literature 
at the national as well as international level. We, therefore, infer from 
the above study that Chennai, despite its hot and arid climate, varying 
ethnicity, food habits, and living standards is very much a part of 
diabetes spectrum the world over.  
 
➢ We did not define or control for maternal ethnicity, which is a known 
risk factor for the development of both gestational and type 2 DM.  
 
➢ The physicians in our study were not revealed about the patients’ DM 
subtype,past medical and obstetrical history, or foetal status.  
 
➢ We did not control for maternal co‐morbidity, such as the presence of 
diabetic nephropathy. These factors may have influenced the 
obstetricians ‘choice regarding timing and mode of delivery, and the 
paediatricians’ decision to admit a newborn to the NICU. 
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CONCLUSION 
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➢ The prevalence of the GDM in the current study is 14.85% 
 
➢ The risk factors for GDM are increased maternal age, multiparity, 
obesity, poor past obstetric history, family history of diabetes, previous 
history of GDM. 
 
 
➢ In this study there was increased association of GDM with poly 
hydramnios, pre-eclampsia, operative delivery, preterm birth. 
 
➢ There was a higher risk of intra uterine death, congenital malformation, 
respiratory distress syndrome, transient tachypnoea of new born, 
macrosomia, neonatal hypoglycaemia in neonates. 
 
 
➢ Women with GDM and their off springs are at increased risk of 
developing type 2 diabetes later in life. In our postnatal follow-up it was 
found that 27.8% of the women turned into type 2 diabetes mellitus. 
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➢ Hence considering the risk to the mother and the baby, both during 
pregnancy and perinatal period, screening of GDM and identifying those 
at risk is important for subsequent management and reduction of 
maternal and perinatal morbidity and mortality. 
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PROFORMA 
 
➢ NAME  
➢ AGE 
➢ IP NO  
➢ PARITY  
➢ FAMILY H/O DIABETES 
➢ PREVIOUS OBSTETRIC HISTORY 
➢ PREVIOUS  H/O GDM  
➢ LMP/EDD  
➢ WEIGHT GAIN DURING PREGNANCY (kg) 
➢ BMI  
➢ GCT 
➢ MANAGEMENT BASED ON GCT 
➢ HIGH RISKS DURING PREGNANCY AND DELIVERY 
➢ BABY DETAILS  
• Mode of delivery 
• Sex of baby 
• Birth weight 
• APGAR 
• Mother side/ admitted 
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➢ POST PARTUM FOLLOW UP AND MANAGEMENT 
Immediate postpartum fasting and post prandial sugar levels 
6weeks postpartum fasting sugar levels 
 
                       Less than 100                                 More than 100 
                      Follow up 3 yearly               Do GTT and treat accordingly 
                                                                            Follow up yearly  
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தகவல் தாள் 
• நாங்கள், கரப்்பக்காலநீரிழிவு (GDM) உள்ளது என 
கண்டறியப்படட்ுள்ள நநாயாளிகளுக்கு ஒரு ஆய்வு நடத்தி 
வருகின்ந ாம். இந்த ஆய்வில் உங்கள் பங்நக ்பு பபருமதிப்பு 
வாய்ந்தது. 
• இந்த ஆய்வின் நநாக்கம் கரப்்பக்கால நீரிழிவுநநாய் 
பபண்களுக்கு தாய்வழி ம ்றும் பி ப்பு சாரந்்த இ ப்பு ம ்றும் 
நநாய் உள்ளத ்கு மதிப்பீடு பசய்வதாகும். 
• நாங்கள்,கரப்்பக்காலநீரிழிவு நநாயய கண்டறிய உங்கள் முதல் 
கரப்்பக்கால மருத்துவமயன வருயகயின் நபாது சரக்்கயர 
சகிப்பு தன்யம  நசாதயன (GTT) பசய்கிந ாம்.  
• பி கு உங்கள் கரப்்பக்காலம் முழுவதும் பதாடரந்்து 
கண்காணித்து தங்களின் பிரசவமுய யயயும் நமலும் உங்கள் 
குழந்யதயின் நியலயயயும் கண்காணிப்நபாம். 
• பிரசவத்தி ்கு பின் 6 வாரங்கள் கழிதத்ு சரக்்கயர சகிப்புதன்யம 
நசாதயன (GTT) பசய்து தங்களின் சரக்்கயரவியாதியின் 
தன்யமயயயும் அத ்கான சிகிசய்ச ப ்றியும் பதரிவிப்நபாம். 
• ஆராய்சச்ியில் நநாயாளிகளின் தனியுரியம ஆய்வு முழுவதும் 
பராமரிக்கப்படும். 
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• எந்த ஒரு தகவல் பரிமா ் ம் அல்லது ஆராய்சச்ி வியளவாக 
வழங்கல் நிகழ்வின் நபாது, தங்கயள தனிப்பட்டமுய யில் 
அயடயாளப்படுத்தும் தகவல் பகிரப்படாது. 
• இந்த ஆய்வில் பங்பகடுப்பது தன்னாரவ்ம் பபாறுத்தது. இந்த 
ஆ்ய்வில் பங்நக ்க அல்லது எந்த நநரத்திலும் நவண்டாம் என 
கூறினாலும் மருத்துவ கவனிப்பி ்கு  எந்த ஒரு பாதிப்பும் 
எ ்படாது என உறுதி அளிக்கிந ாம்.  
• இந்த ஆராய்சச்ியின் முடிவு ப ்றி தங்களுக்கு தகவல்  
பதரிவிக்கப்படும். ஆராய்சச்ியின் நடுவில் தங்களின் நநாயயப் 
ப ்றி பாதிப்பான தகவல் பதரிந்தால் அத ்கான தகுந்த 
மருத்துவ ஆநலாசயனயும், சிகிசய்சயும் அளிக்கப்படும்.  
 
 
 
 
 
மருத்துவ ஆராய்சச்ியாளர ்                                                       பங்நக ்பாளர 
யகபயாப்பம்                                                                                   யகபயாப்பம் 
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INFORMATION SHEET 
➢ We are conducting a study of patients who are diagnosed to be diabetic in 
pregnancy. Your participation in the study is very valuable to us. 
 
➢ The purpose of this study is to evaluate the maternal and perinatal 
mortality and morbidity in diabetes mellitus women 
 
 
➢ We will do GTT at your 1st antenatal visit to diagnose GDM. Then you 
will be followed throughout pregnancy and your mode of delivery will be 
monitored.We will also monitor the condition of your baby. After 6 
weeks postpartum a GTT will be done again to monitor your glycemic 
status and further mode of treatment will be explained to you by us. 
 
➢ The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
 
 
 
 
103 
 
➢ Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled.  
 
➢ The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
 
 
 
Signature of investigator                                              Signature of participant 
Date: 
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ABBREVIATIONS USED 
1. Emerg            -     EMERGENCY 
2. IND                 -     INDICATION 
3. LN                   -     LABOUR NATURALE 
4. PROM            -     PREMATURE RUPTURE OF MEMBRANES 
5. m/s                -      MOTHER SIDE 
6. CPD                -     CEPHALO PELVIC DISPROPORTION 
7. MSL                -     MECONIUM STAINED LIQUOR 
8. FTND              -    FULL TERM NORMAL VAGINAL DELIVERY 
9. Prev                -    PREVIOUS 
10.RPT                 -   REPEAT 
     11.ST                    -   STERILISATION 
12.OHA                -  ORAL HYPOGLYCEMIC AGENTS 
     13.GDM               -  GESTATIONAL DIABETES MELLITUS 
     14.T2DM              -  T2 DIABETES MELLITUS 
15.OLIGO             - OLIGOHYDRAMINOS 
     16.IA                      - INDUCED ABORTION 
     17.SA                    - SPONTANEOUS ABORTION 
     18.MA                   - MONTH OF AMENORRHOEA 
     19.EPI                    - EPISIOTOMY 
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     20.CU-T                 - COPPER-T 
     21.PPIUCD            - POSTPARTUM INTRA UTERINE CONTRACEPTIVE  
                                        DEVICE      
     22.LP 1ST DEG       - LACERATED PERINEUM FIRST DEGREE 
     23.NRCTG             - NON- REACTIVE CARDIOTOCOGRAM 
     24.HTN                 - HYPERTENSIVE 
     25.IUD                  - INTRAUTERINE DEVICE 
     26.NVD                 - NORMAL VAGINAL DELIVERY 
      27.LBW                - LOW BIRTH WEIGHT 
      28.RDS                 - RESPIRATORY DISTRESS SYNDROME 
      29.TTN                 - TRANSIENT TACHYPNOEA OF NEWBORN 
      30.BOH                - BAD OBSTETRIC HISTORY 
      31.F                      - FASTING 
      32.PP                   - POSTPRANDIAL 
      33.PL                   - PRELUNCH 
      34.POL                - POSTLUNCH 
      35.PD                  - PREDINNER 
     36.POD               - POSTDINNER 
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